Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 7, 2005; 11(21): 3182-3188
Published online Jun 7, 2005. doi: 10.3748/wjg.v11.i21.3182
Published online Jun 7, 2005. doi: 10.3748/wjg.v11.i21.3182
n | CDX2 negative | CDX2 positive | ||
All cases | 190 | 81 | 109 | |
MUC2 negative | 149 | 72 | 77 | |
MUC2 positive | 41 | 9 | 32 | |
P | 0.003 | |||
Intestinal type (Laurén) | 70 | 30 | 40 | |
MUC2 negative | 52 | 26 | 26 | |
MUC2 positive | 18 | 4 | 14 | |
P | 0.04 | |||
Diffuse type (Laurén) | 105 | 44 | 61 | |
MUC2 negative | 86 | 41 | 45 | |
MUC2 positive | 19 | 3 | 16 | |
P | 0.01 | |||
Stage I (pTNM) | 53 | 24 | 29 | |
MUC2 negative | 46 | 24 | 22 | |
MUC2 positive | 7 | 0 | 7 | |
P | 0.01 |
- Citation: Roessler K, Mönig SP, Schneider PM, Hanisch FG, Landsberg S, Thiele J, Hölscher AH, Dienes HP, Baldus SE. Co-expression of CDX2 and MUC2 in gastric carcinomas: Correlations with clinico-pathological parameters and prognosis. World J Gastroenterol 2005; 11(21): 3182-3188
- URL: https://www.wjgnet.com/1007-9327/full/v11/i21/3182.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i21.3182